Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer, but da­ta caveats damp­en ex­cite­ment

BARCELONA — Bris­tol My­ers Squibb’s LAG-3 ap­proach has shown po­ten­tial in cer­tain lung can­cer pa­tients in a Phase 2 study, but “cher­ry-picked” analy­sis comes with its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER